Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Nearly 80% of Japanese Support Insurance Coverage for High-Priced Drugs: Nonprofit Survey
September 18, 2019
- Strengthening Regulatory Science Will Accelerate Innovation in Drug Discovery: JPMA President
September 10, 2019
- Bristol-Myers CEO Caforio Named New PhRMA Chair, Tokyo Visit in October
September 6, 2019
- Number of Sales Reps in Japan Falls Below 60,000 in FY2018, Records 5 Consecutive Years of Decline
August 30, 2019
- Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs
August 29, 2019
- Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
August 26, 2019
- Lab Test Group Seeks Better Reimbursement Rules for Cancer Gene Panel Testing
August 21, 2019
- Sales Rose Only Slightly, but Drug Wholesalers Still Improved Profit Rates in FY2018: JPWA
August 16, 2019
- Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
- OTC Groups Call for Enhancing Self-Medication Tax Break, Submit Request
July 19, 2019
- Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
- FPMAJ Asks Member Drug Makers to Conduct Self-Inspections to Ensure Stable Supplies
July 11, 2019
- Generic Association Aims to Contribute to Pre-Symptomatic and Preventive Care: New Industry Vision
July 9, 2019
- JPMA Pushing Teleworking for Member Companies
July 5, 2019
- Generic Use Rate at 74.0% in FY2018: JGA
July 1, 2019
- Govt’s 2019 Honebuto Policy Generally in Line with JPMA Views: President
June 28, 2019
- Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019
- OTC Group Unveils Reform Requests for Self-Medication Tax Break
June 25, 2019
- Further Pricing Discussions Needed for Pricey Products beyond Kymriah: JMA Chief
June 25, 2019
- Health Insurance Coverage Necessary for Risk Reducing Treatments for BRCA Positive Patients: Cancer Bodies
June 21, 2019
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…